The FDA granted accelerated approval Tuesday to Nelkarmi, a targeted treatment for adults with previously treated, advanced ALK-positive non-small cell lung cancer.
ALK is short for anaplastic lymphoma kinase. Changes in its gene or excess ALK protein can help cancer cells grow, the National Cancer Institute explains.
The medicine, also called neladalkib, adds an option for patients with specific treatment histories. The FDA's approval notice covers adults with locally advanced or metastatic disease who previously received either alectinib as their one prior ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy.
Those earlier treatments must have been given in the unresectable locally advanced or metastatic setting. The drug is taken orally once daily.
Who was studied and what the results show
The approval rests on ALKOVE-1, an open-label, single-arm trial. The two groups supporting approval had different treatment histories:
| Prior treatment group | Patients | Tumor response rate | Responders with responses lasting at least 12 months |
|---|---|---|---|
| One prior ALK inhibitor: alectinib | 67 | 49% | 52% |
| Two or more ALK inhibitors and platinum-based chemotherapy | 155 | 32% | 51% |
The duration figures apply to patients whose tumors responded. They do not mean half of everyone treated had a response lasting a year.
The study measured confirmed tumor response and how long responses lasted, with an independent review of results. Its single-arm design means it did not compare Nelkarmi with another treatment assigned at random. The response rates also come from different patient groups and do not establish that one treatment sequence is superior.
What accelerated approval means

The FDA's accelerated approval program permits earlier approval for serious conditions using a measure that is expected to predict clinical benefit. Companies must still conduct studies to confirm that benefit.
For Nelkarmi, approval is based on tumor response rate and duration of response. Those outcomes do not, by themselves, establish that patients live longer. Continued approval may depend on verification of clinical benefit in a confirmatory trial, according to GSK's announcement.
Patients receiving targeted therapy generally undergo regular examinations, blood tests and imaging to assess how treatment is working, the National Cancer Institute explains. A tumor's molecular target and its response over time help shape treatment decisions.
Safety checks remain necessary
Nelkarmi's warnings include liver, kidney and eye toxicity, increases in the muscle enzyme creatine phosphokinase, and potential harm to a fetus. GSK's safety information describes monitoring of liver and kidney function, muscle-enzyme levels and vision during treatment.
Common adverse reactions include liver toxicity, musculoskeletal pain, constipation, changes in taste, nerve problems, swelling and fatigue.
The National Cancer Institute notes that cancer can become resistant to a targeted medicine when the target changes or the tumor finds another way to grow. Targeted therapies can also cause serious side effects.
GSK is separately studying neladalkib in ALKAZAR, an ongoing phase III trial for ALK-positive lung cancer patients who have not received an ALK inhibitor. Tuesday's approval covers the specified previously treated groups.




